Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous neurodegenerative disease with a strong genetic component. In this review, we summarize most common mutations in MAPT, GRN, and C90RF72, as well as less common mutations in VCP, CHMP2B, TARDBP, FUS gene and so on. Several guidelines have been developed to help gene testing based on genotype–phenotype correlation, the underlying histopathological subtypes, and the neuroanatomic associations. Furthermore, we also summarize molecular pathways implicated by genes and novel targets for FTLD prevention and management in recent years.
MackenzieIR, NeumannM, BaborieA, SampathuDM, Du PlessisD, JarosE, PerryRH, TrojanowskiJQ, MannDM, LeeVM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol122, 111–113.
6.
NeumannM, RademakersR, RoeberS, BakerM, KretzschmarHA, MackenzieIR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain132, 2922–2931.
7.
NgAS, RademakersR, MillerBL (2015) Frontotemporal dementia: A bridge between dementia and neuromuscular disease. Ann N Y Acad Sci1338, 71–93.
8.
PoorkajP, BirdTD, WijsmanE, NemensE, GarrutoRM, AndersonL, AndreadisA, WiederholtWC, RaskindM, SchellenbergGD (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol43, 815–825.
9.
SiebenA, Van LangenhoveT, EngelborghsS, MartinJJ, BoonP, CrasP, De DeynPP, SantensP, Van BroeckhovenC, CrutsM (2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol124, 353–372.
10.
SpillantiniMG, GoedertM (2013) Tau pathology and neurodegeneration. Lancet Neurol12, 609–622.
11.
LashleyT, RohrerJD, MeadS, ReveszT (2015) Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol41, 858–881.
KortvelyessyP, GukasjanA, Sweeney-ReedCM, HeinzeHJ, ThurnerL, BittnerDM (2015) Progranulin and Amyloid-beta levels: Relationship to neuropsychology in frontotemporal and Alzheimer’s disease. J Alzheimers Dis46, 375–380.
14.
PetkauTL, LeavittBR (2014) Progranulin in neurodegenerative disease. Trends Neurosci37, 388–398.
15.
HoraitisO, TalbotCCJr, PhommarinhM, PhillipsKM, CottonRG (2007) A database of locus-specific databases. Nat Genet39, 425.
16.
PietroboniAM, FumagalliGG, GhezziL, FenoglioC, CortiniF, SerpenteM, CantoniC, RotondoE, CortiP, CarecchioM, BassiM, BresolinN, GalbiatiD, GalimbertiD, ScarpiniE (2011) Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. J Alzheimers Dis24, 253–259.
17.
RaineroI, RubinoE, NegroE, GalloneS, GalimbertiD, GentileS, ScarpiniE, PinessiL (2011) Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene. Biol Psychiatry70, e43–e44.
18.
Le BerI (2013) Genetics of frontotemporal lobar degeneration: An up-date and diagnosis algorithm. Rev Neurol169, 811–819.
19.
Le BerI, CamuzatA, HannequinD, PasquierF, GuedjE, Rovelet-LecruxA, Hahn-BarmaV, van der ZeeJ, ClotF, BakchineS, PuelM, GhanimM, LacomblezL, MikolJ, DeramecourtV, LejeuneP, de la SayetteV, BelliardS, VercellettoM, MeyrignacC, Van BroeckhovenC, LambertJC, VerpillatP, CampionD, HabertMO, DuboisB, BriceA, French research network on FF-M (2008) Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study. Brain131, 732–746.
20.
BonviciniC, MilanesiE, PilottoA, CattaneN, PremiE, ArchettiS, PadovaniA, GennarelliM, BorroniB (2014) Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. Neurobiol Aging35, 1206–1211.
BeerAM, Cooper-KnockJ, HigginbottomA, HighleyJR, WhartonSB, IncePG, MilanoA, JonesAA, Al-ChalabiA, KirbyJ, ShawPJ (2015) Intermediate length C9orf72 expansion in an ALS patient without classical C9orf72 neuropathology. Amyotroph Lateral Scler Frontotemporal Degener16, 249–251.
23.
XiZ, van BlitterswijkM, ZhangM, McGoldrickP, McLeanJR, YunusovaY, KnockE, MorenoD, SatoC, McKeeverPM, SchneiderR, KeithJ, PetrescuN, FraserP, TartagliaMC, BakerMC, Graff-RadfordNR, BoylanKB, DicksonDW, MackenzieIR, RademakersR, RobertsonJ, ZinmanL, RogaevaE (2015) Jump from pre-mutation to pathologic expansion in C9orf72. Am J Hum Genet96, 962–970.
24.
AkimotoC, VolkAE, van BlitterswijkM, Van den BroeckM, LeblondCS, LumbrosoS, CamuW, NeitzelB, OnoderaO, van RheenenW, PintoS, WeberM, SmithB, ProvenM, TalbotK, KeagleP, ChesiA, RattiA, van der ZeeJ, AlstermarkH, BirveA, CaliniD, NordinA, TradowskyDC, JustW, DaoudH, AngerbauerS, DeJesus-HernandezM, KonnoT, Lloyd-JaniA, de CarvalhoM, MouzatK, LandersJE, VeldinkJH, SilaniV, GitlerAD, ShawCE, RouleauGA, van den BergLH, Van BroeckhovenC, RademakersR, AndersenPM, KubischC (2014) A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet51, 419–424.
25.
LevineTP, DanielsRD, GattaAT, WongLH, HayesMJ (2013) The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics29, 499–503.
26.
Cooper-KnockJ, KirbyJ, HighleyR, ShawPJ (2015) The spectrum of C9orf72-mediated neurodegeneration and amyotrophic lateral sclerosis. Neurotherapeutics12, 326–339.
Le BerI (2015) Frontotemporal lobar dementia and amyotrophic lateral sclerosis associated with c9orf72 expansion. Rev Neurol (Paris)171, 475–481.
29.
SuhE, LeeEB, NealD, WoodEM, ToledoJB, RennertL, IrwinDJ, McMillanCT, KrockB, ElmanLB, McCluskeyLF, GrossmanM, XieSX, TrojanowskiJQ, Van DeerlinVM (2015) Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol130, 363–372.
30.
RussJ, LiuEY, WuK, NealD, SuhE, IrwinDJ, McMillanCT, HarmsMB, CairnsNJ, WoodEM, XieSX, ElmanL, McCluskeyL, GrossmanM, Van DeerlinVM, LeeEB (2015) Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol129, 39–52.
31.
LiuY, YuJT, SunFR, OuJR, QuSB, TanL (2013) The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations. J Neurol Sci335, 26–35.
32.
GalimbertiD, ReifA, Dell’OssoB, PalazzoC, VillaC, FenoglioC, Kittel-SchneiderS, LeonhardC, OlmesDG, SerpenteM, PaoliRA, AltamuraAC, ScarpiniE (2014) C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. Bipolar Disord16, 448–449.
33.
GalimbertiD, ReifA, Dell’ossoB, Kittel-SchneiderS, LeonhardC, HerrA, PalazzoC, VillaC, FenoglioC, SerpenteM, CioffiSM, PrunasC, PaoliRA, AltamuraAC, ScarpiniE (2014) C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiol Aging, 35, 1214e1217–1214e1210.
34.
SoljeE, MiettunenJ, MarttilaR, HelisalmiS, LaitinenM, Koivumaa-HonkanenH, IsohanniM, HiltunenM, JaaskelainenE, RemesAM (2016) The C9ORF72 expansion sizes in patients with psychosis: A population-based study on the Northern Finland Birth Cohort 1966. Psychiatr Genet26, 92–94.
35.
SouzaPV, PintoWB, OliveiraAS (2015) C9orf72-related disorders: Expanding the clinical and genetic spectrum of neurodegenerative diseases. Arq Neuropsiquiatr73, 246–256.
SandersP, EwingI, AhmadK (2016) C9orf72 expansion presenting as an eating disorder. J Clin Neurosci25, 157–159.
38.
FlorisG, BorgheroG, CannasA, Di StefanoF, RuiuE, MurruMR, CorongiuD, CuccuS, TranquilliS, SarduC, MarrosuMG, ChioA, MarrosuF (2015) Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. Amyotroph Lateral Scler Frontotemporal Degener16, 8–15.
39.
SnowdenJS, HarrisJ, AdamsJ, ThompsonJC, RichardsonAM, JonesMS, NearyD, DavidsonYS, RobinsonAC, RollinsonS, Pickering-BrownS, MannDM (2015) Psychosis associated with expansions in the C9orf72 gene: The influence of a 10 base pair gene deletion. J Neurol Neurosurg Psychiatry, doi: 10.1136/jnnp-2015-310441
40.
Simon-SanchezJ, DopperEG, Cohn-HokkePE, HukemaRK, NicolaouN, SeelaarH, de GraafJR, de KoningI, van SchoorNM, DeegDJ, SmitsM, RaaphorstJ, van den BergLH, SchelhaasHJ, De Die-SmuldersCE, Majoor-KrakauerD, RozemullerAJ, WillemsenR, PijnenburgYA, HeutinkP, van SwietenJC (2012) The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain135, 723–735.
41.
SmithBN, NewhouseS, ShatunovA, VanceC, ToppS, JohnsonL, MillerJ, LeeY, TroakesC, ScottKM, JonesA, GrayI, WrightJ, HortobagyiT, Al-SarrajS, RogeljB, PowellJ, LuptonM, LovestoneS, SappPC, WeberM, NestorPJ, SchelhaasHJ, AsbroekAA, SilaniV, GelleraC, TaroniF, TicozziN, Van den BergL, VeldinkJ, Van DammeP, RobberechtW, ShawPJ, KirbyJ, PallH, MorrisonKE, MorrisA, de BellerocheJ, Vianney de JongJM, BaasF, AndersenPM, LandersJ, BrownRHJr, WealeME, Al-ChalabiA, ShawCE (2013) The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet21, 102–108.
42.
LiuY, YuJ-T, SunF-R, OuJ-R, QuS-B, TanL (2013) The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations. J Neurol Sci335, 26–35.
43.
DekkerAM, SeelenM, van DoormaalPT, van RheenenW, BothofRJ, van RiessenT, BrandsWJ, van der KooiAJ, de VisserM, VoermansNC, PasterkampRJ, VeldinkJH, van den BergLH, van EsMA (2016) Large-scale screening in sporadic amyotrophic lateral sclerosis identifies genetic modifiers in C9orf72 repeat carriers. Neurobiol Aging39, 220.e9-220.e15.
44.
BenatarM, WuuJ, FernandezC, WeihlCC, KatzenH, SteeleJ, OskarssonB, TaylorJP (2013) Motor neuron involvement in multisystem proteinopathy: Implications for ALS. Neurology80, 1874–1880.
45.
FerrariR, HardyJ, MomeniP (2011) Frontotemporal dementia: From Mendelian genetics towards genome wide association studies. J Mol Neurosci45, 500–515.
46.
WeihlCC, PestronkA, KimonisVE (2009) Valosin-containing protein disease: Inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementia. Neuromuscul Disord19, 308–315.
47.
WeihlCC (2011) Valosin containing protein associated fronto-temporal lobar degeneration: Clinical presentation, pathologic features and pathogenesis. Curr Alzheimer Res8, 252–260.
48.
CeramiC, ScarpiniE, CappaSF, GalimbertiD (2012) Frontotemporal lobar degeneration: Current knowledge and future challenges. J Neurol259, 2278–2286.
49.
SpinaS, Van LaarAD, MurrellJR, HamiltonRL, KoflerJK, EppersonF, FarlowMR, LopezOL, QuinlanJ, DeKoskyST, GhettiB (2013) Phenotypic variability in three families with valosin-containing protein mutation. Eur J Neurol20, 251–258.
ChassefeyreR, Martinez-HernandezJ, BertasoF, BouquierN, BlotB, LaporteM, FrabouletS, CouteY, DevoyA, IsaacsAM, Pernet-GallayK, SadoulR, FagniL, GoldbergY (2015) Regulation of postsynaptic function by the dementia-related ESCRT-III subunit CHMP2B. J Neurosci35, 3155–3173.
52.
CheruiyotA, LeeJA, GaoFB, AhmadST (2014) Expression of mutant CHMP2B, an ESCRT-III component involved in frontotemporal dementia, causes eye deformities due to Notch misregulation in Drosophila. FASEB J28, 667–675.
53.
LuY, ZhangZ, SunD, SweeneyST, GaoFB (2013) Syntaxin 13, a genetic modifier of mutant CHMP2B in frontotemporal dementia, is required for autophagosome maturation. Mol Cell52, 264–271.
54.
WestRJ, LuY, MarieB, GaoFB, SweeneyST (2015) Rab8, POSH, and TAK1 regulate synaptic growth in a Drosophila model of frontotemporal dementia. J Cell Biol208, 931–947.
55.
MackenzieIR, NeumannM, CairnsNJ, MunozDG, IsaacsAM (2011) Novel types of frontotemporal lobar degeneration: Beyond tau and TDP-43. J Mol Neurosci45, 402–408.
56.
StokholmJ, TeasdaleTW, JohannsenP, NielsenJE, NielsenTT, IsaacsA, BrownJM, GadeA (2013) Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: A longitudinal prospective study. J Neurol Neurosurg Psychiatry84, 170–176.
Vanden BroeckL, KleinbergerG, ChapuisJ, GistelinckM, AmouyelP, Van BroeckhovenC, LambertJC, CallaertsP, DermautB (2015) Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: Evidence for a loss-of-function mechanism. Neurobiol Aging36, 1121–1129.
GuerreiroR, KaraE, Le BerI, BrasJ, RohrerJD, TaipaR, LashleyT, DupuitsC, GurunlianN, MochelF, WarrenJD, HannequinD, SedelF, DepienneC, CamuzatA, GolfierV, Du BoisgueheneucF, SchottlaenderL, FoxNC, BeckJ, MeadS, RossorMN, HardyJ, ReveszT, BriceA, HouldenH (2013) Genetic analysis of inherited leukodystrophies: Genotype-phenotype correlations in the CSF1R gene. JAMA Neurol70, 875–882.
66.
KovacsGG, van der ZeeJ, HortJ, KristoferitschW, LeithaT, HoftbergerR, StrobelT, Van BroeckhovenC, MatejR (2016) Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. Neuropathology36, 27–38.
67.
Le BerI, CamuzatA, GuerreiroR, Bouya-AhmedK, BrasJ, NicolasG, GabelleA, DidicM, De SeptenvilleA, MillecampsS, LengletT, LatoucheM, KabashiE, CampionD, HannequinD, HardyJ, BriceA (2013) SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol70, 1403–1410.
68.
Le BerI, De SeptenvilleA, MillecampsS, CamuzatA, CaroppoP, CouratierP, BlancF, LacomblezL, SellalF, FleuryMC, MeiningerV, CazeneuveC, ClotF, FlabeauO, LeGuernE, BriceA (2015) TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol Aging36, 3116e3115-3118.
69.
WeidbergH, ElazarZ (2011) TBK1 mediates crosstalk between the innate immune response and autophagy. Sci Signal4, pe39.
70.
PottierC, BieniekKF, FinchN, van de VorstM, BakerM, PerkersenR, BrownP, RavenscroftT, van BlitterswijkM, NicholsonAM, DeTureM, KnopmanDS, JosephsKA, ParisiJE, PetersenRC, BoylanKB, BoeveBF, Graff-RadfordNR, VeltmanJA, GilissenC, MurrayME, DicksonDW, RademakersR (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol130, 77–92.
71.
Van MosseveldeS, van der ZeeJ, GijselinckI, EngelborghsS, SiebenA, Van LangenhoveT, De BleeckerJ, BaetsJ, VandenbulckeM, Van LaereK, CeyssensS, Van den BroeckM, PeetersK, MattheijssensM, CrasP, VandenbergheR, De JongheP, MartinJJ, De DeynPP, CrutsM, Van BroeckhovenC, Belgian Neurology consortium (2016) Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain139, 452–467.
72.
van der ZeeJ, Van LangenhoveT, KleinbergerG, SleegersK, EngelborghsS, VandenbergheR, SantensP, CrasP, De DeynPP, CrutsM, Van BroeckhovenC (2010) TMEM106B the first common risk factor for FTLD: Replication in a clinically diagnosed cohort of FTLD patients. Alzheimers Dement6, S75–S76.
StefaniF, ZhangL, TaylorS, DonovanJ, RollinsonS, DoyotteA, BrownhillK, BennionJ, Pickering-BrownS, WoodmanP (2011) UBAP1 is a component of an endosome-specific ESCRT-I complex that is essential for MVB sorting. Curr Biol21, 1245–1250.
ChaussenotA, Le BerI, Ait-El-MkademS, CamuzatA, de SeptenvilleA, BannwarthS, GeninEC, SerreV, AugeG, BriceA, PougetJ, Paquis-FlucklingerV (2014) Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. Neurobiol Aging35, 2884e2881–2884.
77.
LattanteS, MillecampsS, StevaninG, Rivaud-PechouxS, MoigneuC, CamuzatA, Da BarrocaS, MundwillerE, CouarchP, SalachasF, HannequinD, MeiningerV, PasquierF, SeilheanD, CouratierP, Danel-BrunaudV, BonnetAM, TranchantC, LeGuernE, BriceA, Le BerI, KabashiE (2014) Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology83, 990–995.
78.
BernardiL, CupidiC, FrangipaneF, AnfossiM, GalloM, ConidiME, VassoF, ColaoR, PuccioG, CurcioSAM, MirabelliM, ClodomiroA, Di LorenzoR, SmirneN, MalettaR, BruniAC (2014) Novel N-terminal domain mutation in prion protein detected in 2 patients diagnosed with frontotemporal lobar degeneration syndrome. Neurobiol Aging35, 2657.e2657–2657.e2611.
79.
NewswayV, FishM, RohrerJD, MajounieE, WilliamsN, HackM, WarrenJD, MorrisHR (2010) Perry syndrome due to the DCTN1 G71R mutation: A distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure. Mov Disord25, 767–770.
80.
RohrerJD, RidgwayGR, ModatM, OurselinS, MeadS, FoxNC, RossorMN, WarrenJD (2010) Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage53, 1070–1076.
Graff-RadfordJ, JonesD, WeigandS, PrzybelskiS, WhitwellJL, SenjemM, KnopmanDS, Graff-RadfordNR, JosephsK, WszolekZ, VemuriP, FieldsJA, FermanTJ, LucasJ, LoweVJ, GavrilovaR, KuntzK, DeJesus HernandezM, BakerM, RademakersR, PetersenRC, KantarciK, JackC, BoeveBF (2014) Longitudinal MRI and neuropsychological changes in symptomatic frontotemporal lobar degeneration subjects with mutations in MAPT, PGRN, and C9ORF72. Alzheimers Dement10, P213–P214.
83.
McMillanCT, ToledoJB, AvantsBB, CookPA, WoodEM, SuhE, IrwinDJ, PowersJ, OlmC, ElmanL, McCluskeyL, SchellenbergGD, LeeVM, TrojanowskiJQ, Van DeerlinVM, GrossmanM (2014) Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiol Aging35, 1473–1482.
84.
ZhangCC, XingA, TanMS, TanL, YuJT (2015) The role of MAPT in neurodegenerative diseases: Genetics, mechanisms and therapy. Mol Neurobiol, doi: 10.1007/s12035-015-9415-8
85.
ButzlaffM, HannanSB, KarstenP, LenzS, NgJ, VossfeldtH, PrussingK, PflanzR, SchulzJB, RasseT, VoigtA (2015) Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. Hum Mol Genet24, 3623–3637.
86.
NaasanG, RabinoviciGD, GhoshP, ElofsonJD, MillerBL, CoppolaG, KarydasA, FongJ, PerryD, LeeSE, YokoyamaJS, SeeleyWW, KramerJH, WeinerMW, SchuffN, JagustWJ, GrinbergLT, PribadiM, YangZ, SearsR, KleinE, WojtaK, RosenHJ (2016) Amyloid in dementia associated with familial FTLD: Not an innocent bystander. Neurocase22, 76–83.
AlquezarC, EsterasN, BartolomeF, MerinoJJ, AlzualdeA, Lopez de MunainA, Martin-RequeroA (2012) Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia. Neurobiol Aging33, 429e427–420.
91.
GötzlJ, MoriK, DammeM, FellererK, TahirovicS, KleinbergerG, JanssensJ, van der ZeeJ, LangC, KremmerE, MartinJ, EngelborghsS, KretzschmarH, ArzbergerT, Van BroeckhovenC, HaassC, CapellA (2014) Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol127, 845–860.
92.
RaitanoS, OrdovasL, De MuynckL, GuoW, Espuny-CamachoI, GeraertsM, KhuranaS, VanuytselK, TothBI, VoetsT, VandenbergheR, CathomenT, Van Den BoschL, VanderhaeghenP, Van DammeP, VerfaillieCM (2015) Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia. Stem Cell Reports4, 16–24.
93.
HosokawaM, AraiT, Masuda-SuzukakeM, KondoH, MatsuwakiT, NishiharaM, HasegawaM, AkiyamaH (2015) Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. J Neuropathol Exp Neurol74, 158–165.
94.
JanssensJ, PhiltjensS, KleinbergerG, Van MosseveldeS, van der ZeeJ, CacaceR, EngelborghsS, SiebenA, Banzhaf-StrathmannJ, DillenL, MerlinC, CuijtI, RobberechtC, SchmidB, SantensP, IvanoiuA, VandenbulckeM, VandenbergheR, CrasP, De DeynPP, MartinJJ, MaudsleyS, HaassC, CrutsM, Van BroeckhovenC (2015) Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathol Commun3, 68.
WangJ, HaeuslerAR, SimkoEA (2015) Emerging role of RNA*DNA hybrids in C9orf72-linked neurodegeneration. Cell Cycle14, 526–532.
97.
MackenzieIR, FrickP, NeumannM (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol127, 347–357.
98.
XiZ, ZinmanL, MorenoD, SchymickJ, LiangY, SatoC, ZhengY, GhaniM, DibS, KeithJ, RobertsonJ, RogaevaE (2013) Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet92, 981–989.
99.
BelzilVV, BauerPO, PrudencioM, GendronTF, StetlerCT, YanIK, PregentL, DaughrityL, BakerMC, RademakersR, BoylanK, PatelTC, DicksonDW, PetrucelliL (2013) Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol126, 895–905.
100.
XiZ, ZhangM, BruniAC, MalettaRG, ColaoR, FrattaP, PolkeJM, SweeneyMG, MudanohwoE, NacmiasB, SorbiS, TartagliaMC, RaineroI, RubinoE, PinessiL, GalimbertiD, SuraceEI, McGoldrickP, McKeeverP, MorenoD, SatoC, LiangY, KeithJ, ZinmanL, RobertsonJ, RogaevaE (2015) The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol129, 715–727.
101.
VatovecS, KovandaA, RogeljB (2014) Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neurobiol Aging35, 2421.e2421–2421.e2412.
102.
Lagier-TourenneC, BaughnM, RigoF, SunS, LiuP, LiHR, JiangJ, WattAT, ChunS, KatzM, QiuJ, SunY, LingSC, ZhuQ, PolymenidouM, DrennerK, ArtatesJW, McAlonis-DownesM, MarkmillerS, HuttKR, PizzoDP, CadyJ, HarmsMB, BalohRH, VandenbergSR, YeoGW, FuXD, BennettCF, ClevelandDW, RavitsJ (2013) Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A110, E4530–E4539.
103.
GriggJC, ShumayrikhN, SenD (2014) G-quadruplex structures formed by expanded hexanucleotide repeat RNA and DNA from the neurodegenerative disease-linked C9orf72 gene efficiently sequester and activate heme. PLoS One9, e106449.
ZuT, LiuY, Banez-CoronelM, ReidT, PletnikovaO, LewisJ, MillerTM, HarmsMB, FalchookAE, SubramonySH, OstrowLW, RothsteinJD, TroncosoJC, RanumLP (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A110, E4968–E4977.
108.
AshPE, BieniekKF, GendronTF, CaulfieldT, LinWL, Dejesus-HernandezM, van BlitterswijkMM, Jansen-WestK, PaulJW3rd, RademakersR, BoylanKB, DicksonDW, PetrucelliL (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron77, 639–646.
109.
YamakawaM, ItoD, HondaT, KuboK, NodaM, NakajimaK, SuzukiN (2015) Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Hum Mol Genet24, 1630–1645.
110.
TaoZ, WangH, XiaQ, LiK, LiK, JiangX, XuG, WangG, YingZ (2015) Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum Mol Genet24, 2426–2441.
111.
JovicicA, MertensJ, BoeynaemsS, BogaertE, ChaiN, YamadaSB, PaulJW3rd, SunS, HerdyJR, BieriG, KramerNJ, GageFH, Van Den BoschL, RobberechtW, GitlerAD (2015) Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci18, 1226–1229.
SchludiMH, MayS, GrässerFA, RentzschK, KremmerE, KüpperC, KlopstockT, German Consortium for Frontotemporal Lobar Degeneration, Bavarian Brain Banking Alliance, ArzbergerT, EdbauerD (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol130, 537–555.
115.
PortaS, KwongLK, TrojanowskiJQ, LeeVM (2015) Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases. J Neuropathol Exp Neurol74, 380–387.
116.
RubinoE, VaccaA, GovoneF, De MartinoP, PinessiL, RaineroI (2013) Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta-analysis. Alzheimers Dement9, 706–713.
117.
LourencoGF, JanitzM, HuangY, HallidayGM (2015) Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiol Dis82, 445–454.
118.
XiaY, YanLH, HuangB, LiuM, LiuX, HuangC (2014) Pathogenic mutation of UBQLN2 impairs its interaction with UBXD8 and disrupts endoplasmic reticulum-associated protein degradation. J Neurochem129, 99–106.
119.
GuerreiroR, BrasJ, HardyJ (2015) SnapShot: Genetics of ALS and FTD. Cell160, 798.e791
120.
PremiE, ArchettiS, PilottoA, SeripaD, PagheraB, PadovaniA, BorroniB (2015) Functional genetic variation in the serotonin 5-HTTLPR modulates brain damage in frontotemporal dementia. Neurobiol Aging36, 446–451.
121.
LoyCT, SchofieldPR, TurnerAM, KwokJB (2014) Genetics of dementia. Lancet383, 828–840.
122.
CaroppoP, Le BerI, CamuzatA, ClotF, NaccacheL, LamariF, De SeptenvilleA, BertrandA, BelliardS, HannequinD, ColliotO, BriceA (2014) Extensive white matter involvement in patients with frontotemporal lobar degeneration: Think progranulin. JAMA Neurol71, 1562–1566.
123.
GhidoniR, StoppaniE, RossiG, PiccoliE, AlbertiniV, PaterliniA, GlionnaM, PegoianiE, AgnatiLF, FenoglioC, ScarpiniE, GalimbertiD, MorbinM, TagliaviniF, BinettiG, BenussiL (2012) Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: A multicenter Italian study. Neurodegener Dis9, 121–127.
124.
Le BerI, CamuzatA, Guillot-NoelL, HannequinD, LacomblezL, GolfierV, PuelM, MartinaudO, DeramecourtV, Rivaud-PechouxS, MillecampsS, VercellettoM, CouratierP, SellalF, PasquierF, SalachasF, Thomas-AnterionC, DidicM, ParienteJ, SeilheanD, RubergM, WargonI, BlancF, CamuW, MichelBF, BergerE, SauveeM, Thauvin-RobinetC, MondonK, Tournier-LasserveE, GoizetC, FleuryM, ViennetG, VerpillatP, MeiningerV, DuyckaertsC, DuboisB, BriceA (2013) C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: A flow-chart for genetic testing. J Alzheimers Dis34, 485–499.
125.
SynofzikM, BornC, RomingerA, LummelN, SchölsL, BiskupS, SchüleC, GrasshoffU, KlopstockT, AdamczykC (2014) Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. Neurobiol Aging35, 1212.e1211–1212.e1215.
126.
WiselyEV, XiangYK, OddoS (2014) Genetic suppression of beta2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. Hum Mol Genet23, 4024–4034.
127.
JiangT, YuJT, ZhuXC, ZhangQQ, CaoL, WangHF, TanMS, GaoQ, QinH, ZhangYD, TanL (2014) Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology85, 121–130.
BoxerAL, GoldM, HueyE, GaoF-B, BurtonEA, ChowT, KaoA, LeavittBR, LambB, GretherM, KnopmanD, CairnsNJ, MackenzieIR, MiticL, RobersonED, Van KammenD, CantillonM, ZahsK, SallowayS, MorrisJ, TongG, FeldmanH, FillitH, DickinsonS, KhachaturianZ, SutherlandM, FareseR, MillerBL, CummingsJ (2013) Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement9, 176–188.
130.
CoutadeurS, BenyamineH, DelalondeL, de OliveiraC, LeblondB, FoucourtA, BessonT, CasagrandeAS, TaverneT, GirardA, PandoMP, DesireL (2015) A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer’s disease: Effect on Tau and amyloid pathologies in vitro. J Neurochem133, 440–451.
131.
WarmusBA, SekarDR, McCutchenE, SchellenbergGD, RobertsRC, McMahonLL, RobersonED (2014) Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia. J Neurosci34, 16482–16495.
132.
BolkanBJ, KretzschmarD (2014) Loss of Tau results in defects in photoreceptor development and progressive neuronal degeneration in Drosophila. Dev Neurobiol74, 1210–1225.
133.
XuH, RoslerTW, CarlssonT, de AndradeA, FialaO, HollerhageM, OertelWH, GoedertM, AignerA, HoglingerGU (2014) Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr Gene Ther14, 343–351.
134.
AdwanL, SubaieaGM, BashaR, ZawiaNH (2015) Tolfenamic acid reduces tau and CDK5 levels: Implications for dementia and tauopathies. J Neurochem133, 266–272.
SandersDW, KaufmanSK, DeVosSL, SharmaAM, MirbahaH, LiA, BarkerSJ, FoleyAC, ThorpeJR, SerpellLC, MillerTM, GrinbergLT, SeeleyWW, DiamondMI (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron82, 1271–1288.
137.
AlbericiA, ArchettiS, PilottoA, PremiE, CossedduM, BianchettiA, SemeraroF, SalvettiM, MuiesanML, PadovaniA, BorroniB (2014) Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation. Neurol Sci35, 1215–1219.
138.
JiaoJ, HerlLD, FareseRV, GaoFB (2010) MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS One5, e10551.
139.
Chen-PlotkinAS, UngerTL, GallagherMD, BillE, KwongLK, Volpicelli-DaleyL, BuschJI, AkleS, GrossmanM, Van DeerlinV, TrojanowskiJQ, LeeVM (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci32, 11213–11227.
140.
MinamiSS, ShenV, LeD, KrabbeG, AsgarovR, Perez-CelajesL, LeeCH, LiJ, Donnelly-RobertsD, GanL (2015) Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with alpha7 nicotinic acetylcholine receptor agonists. Biochem Pharmacol97, 454–462.
RiboldiG, ZanettaC, RanieriM, NizzardoM, SimoneC, MagriF, BresolinN, ComiGP, CortiS (2014) Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol50, 721–732.
143.
SuZ, ZhangY, GendronTF, BauerPO, ChewJ, YangWY, FostvedtE, Jansen-WestK, BelzilVV, DesaroP, JohnstonA, OverstreetK, OhSY, ToddPK, BerryJD, CudkowiczME, BoeveBF, DicksonD, FloeterMK, TraynorBJ, MorelliC, RattiA, SilaniV, RademakersR, BrownRH, RothsteinJD, BoylanKB, PetrucelliL, DisneyMD (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron83, 1043–1050.
144.
ZamiriB, ReddyK, MacgregorRBJr, PearsonCE (2014) TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J Biol Chem289, 4653–4659.
